Table 3.

Summary of subgroup analysis from the ARISTOTLE trial [Hohnloser et al. 2012; Halvorsen et al. 2014; Vinereanu et al. 2015; Easton et al. 2012; Alexander et al. 2014; Avezum et al. 2015].

Subgroup	Stroke and systemic embolism (% per year)			Major bleeding (% per year)			All-cause mortality (% per year)
	Apixaban	Warfarin	p	Apixaban	Warfarin	p	Apixaban	Warfarin	p
Cr Cl ⩾ 80	0.99	1.12	0.71	1.46	1.84	0.03	2.33	2.71	0.63
50 < Cr Cl < 80	1.24	1.69		2.45	3.21		3.41	3.56
Cr Cl ⩽ 50	2.11	2.67		3.21	6.44		7.12	8.30
Age < 80	1.23	1.55	0.91	1.93	2.78	0.74	3.03	3.42	0.73
Age > 80	1.53	1.90		3.55	5.41		6.86	7.44
Women	1.35	1.81	0.45	1.91	3.29	0.06	3.11	3.41	0.83
Men	1.22	1.49		2.26	2.98		3.37	3.75
Prior CVA	2.46	3.24	0.71	2.84	3.91	0.69	4.22	4.77	0.89
No prior CVA	1.01	1.23		1.98	2.91		3.37	3.75
On ASA	1.12	1.91	0.10	3.10	3.92	0.29	3.02	3.61	0.10
Not on ASA	1.11	1.32		1.82	2.78		4.95	4.88
Valvular disease	1.20	1.43	0.38	3.78	5.69	0.12	3.02	3.61	0.10
No valvular disease	1.46	2.08		4.90	6.36		4.95	4.88

Cr Cl, creatinine clearance (calculated by Cockcroft–Gault equation); ASA, aspirin at randomization; CVA, cerebrovascular accident.